The 22G>A polymorphism in the adenosine deaminase gene impairs catalytic function but does not affect reactive hyperaemia in humans in vivo.
Fulltext:
70834.pdf
Embargo:
until further notice
Size:
86.23Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2008Source
Pharmacogenetics and Genomics, 18, 10, (2008), pp. 843-6ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Pharmacology-Toxicology
Human Genetics
Psychiatry
Otorhinolaryngology
Internal Medicine
Former Organization
Pharmacology/Toxicology
Journal title
Pharmacogenetics and Genomics
Volume
vol. 18
Issue
iss. 10
Page start
p. 843
Page end
p. 6
Subject
DCN 1: Perception and Action; DCN 2: Functional Neurogenomics; IGMD 3: Genomic disorders and inherited multi-system disorders; NCEBP 14: Cardiovascular diseases; NCMLS 6: Genetics and epigenetic pathways of disease; UMCN 2.2: Vascular medicine and diabetes; UMCN 3.2: Cognitive neurosciences; UMCN 5.1: Genetic defects of metabolismAbstract
OBJECTIVES: During ischaemia, the extracellular concentration of the endogenous nucleoside adenosine increases rapidly. Subsequent adenosine receptor stimulation induces various effects, including vasodilation, which can protect the tissue against the ischaemic insult. Adenosine deaminase (ADA) is an enzyme that catalyzes the irreversible deamination of adenosine. We hypothesized that the 22G>A polymorphism in the ADA gene inhibits its catalytic activity, and potentiates the protective effects of adenosine. METHODS: In 96 healthy volunteers, blood was drawn to determine the ADA genotype, and the Vmax and Km values of the ADA from isolated erythrocytes. In a subgroup of volunteers (n=40) we measured the forearm vasodilator response to 13 min of forearm ischaemia using venous occlusion plethysmography as a read-out parameter for adenosine receptor stimulation. RESULTS: Although healthy volunteers with the 22GA genotype had a lower Vmax value of ADA than volunteers with the GG genotype (61.6+/-4.3 ng/min/mg, n=14, vs. 78.0+/-2.8 ng/min/mg, n=82; P=0.02), this did not potentiate the forearm vasodilator response to 13 min of ischaemia (77.4+/-8.8 ml/dl in the GA group (n=5) vs. 87.0+/-5.0 ml/dl (n=35), area under the curve, P=0.3). CONCLUSION: We conclude that heterozygosity for the 22G>A variant of ADA, although reducing catalytic activity, does not enhance forearm reactive hyperaemia. Therefore, the 22G>A variant probably does not contribute to any variability in the protective cardiovascular effects of adenosine.
This item appears in the following Collection(s)
- Academic publications [244084]
- Electronic publications [131085]
- Faculty of Medical Sciences [92872]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.